Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash & Equivalents (2016 - 2026)

Myriad Genetics has reported Cash & Equivalents over the past 17 years, most recently at $149.6 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 46.09% to $149.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $149.6 million through Dec 2025, up 46.09% year-over-year, with the annual reading at $149.6 million for FY2025, 46.09% up from the prior year.
  • Cash & Equivalents was $149.6 million for Q4 2025 at Myriad Genetics, up from $145.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $295.2 million in Q3 2021 and troughed at $53.6 million in Q1 2023.
  • The 5-year median for Cash & Equivalents is $103.5 million (2022), against an average of $123.6 million.
  • Year-over-year, Cash & Equivalents surged 149.54% in 2021 and then crashed 77.89% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $257.4 million in 2021, then tumbled by 77.89% to $56.9 million in 2022, then soared by 132.16% to $132.1 million in 2023, then fell by 22.48% to $102.4 million in 2024, then soared by 46.09% to $149.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Cash & Equivalents are $149.6 million (Q4 2025), $145.4 million (Q3 2025), and $74.4 million (Q2 2025).